Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. (Q48202591)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Sergey Orlov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Li Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Fadi Braiteh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Huiqiang Huang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Taito Esaki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Keizo Horibe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jin-Seok Ahn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Joseph T Beck

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

William Jeffrey Edenfield

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Matthew Taylor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Brian A Van Tine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Shang-Ju Wu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jolanda Paolini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Paulina Selaru

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Tae Min Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Carlo Gambacorti-Passerini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

publication date

8 February 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Hematology

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

607-614

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

The role of the ALK receptor in cancer biology

9 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Anaplastic large cell lymphoma in paediatric and young adult patients

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

The genetic landscape of high-risk neuroblastoma

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Anaplastic large cell lymphoma, ALK-positive

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Crizotinib in Anaplastic Large-Cell Lymphoma

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Anaplastic lymphoma kinase: signalling in development and disease

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Activating mutations in ALK provide a therapeutic target in neuroblastoma

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Clinical inquiries. How much can exercise raise creatine kinase level--and does it matter?

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Anaplastic lymphoma kinase proteins in growth control and cancer

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study

19 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947833

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

14 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29352732

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/AJH.25043

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

PubMed publication ID

29352732

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29352732%20AND%20SRC:MED&resulttype=core&format=json